FDA approves Xeris’ GVOKE injection for treatment of severe hypoglycaemia

This article was originally published here

GVOKE is a ready-to-use, room-temperature stable liquid glucagon product, which can be administered to the patient using a prefilled syringe or auto-injector. The liquid glucagon product will be

The post FDA approves Xeris’ GVOKE injection for treatment of severe hypoglycaemia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply